SBH-13859-43119
4 vaccinations
1 coded response
51 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 028 / RI
- Registered
- 2021-04-21
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Registered dependents
K7V-27775-31261
Child or adolescent in my care · Male · 2022-08-09
Timeline
-
2021-04-20
Dose 1 — Pfizer-BioNTech
-
2021-04-21
Registered in v-safe
-
2021-04-21
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Site: Pain · Headache, Fatigue or tirednessAdult check-in
-
2021-04-22
Health check-in — days 1–6 daily, dose 1Feeling: Good · Site: Pain · Fatigue or tirednessAdult check-in
- 2021-04-23
- 2021-04-24
- 2021-04-25
- 2021-04-26
- 2021-04-27
- 2021-05-04
-
2021-05-11
Dose 2 — Pfizer-BioNTech
- 2021-05-11
-
2021-05-12
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fever · Chills, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
- 2021-05-13
- 2021-05-14
- 2021-05-15
- 2021-05-16
- 2021-05-17
- 2021-05-18
- 2021-05-25
- 2021-06-01
- 2021-06-08
- 2021-06-15
- 2021-06-22
- 2021-08-10
- 2021-11-09
-
2021-11-10
Dose 3 — Pfizer-BioNTech
-
2021-11-11
Health check-in — days 1–6 daily, dose 3Feeling: Fair · Site: Pain · Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
- 2021-11-12
- 2021-11-13
- 2021-11-14
- 2021-11-15
- 2021-11-16
- 2021-11-17
- 2021-11-24
- 2021-12-01
- 2021-12-08
- 2021-12-15
- 2021-12-22
-
2022-02-10
Survey response — 3 months, dose 3MedDRA: Gestational hypertension, Postpartum state, Pre-eclampsia — Feeling: Poor · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Emergency room or emergency department visit, HospitalizationFree text: Gestational hypertension and Postpartum preeclampsiaMedDRA releases: 2024-11 · check-in free text available
-
2022-02-10
Report sent to call center — 3 months, dose 3Be unable to do your normal daily activities · Get care from a doctor or other healthcare professionalEmergency room or emergency department visit · Hospitalization · 1 call case(s)
-
2022-02-11
Call successfulNot applicable (accidental reporting or does not believe symptoms are related to vaccine)
- 2022-05-13
-
2022-09-15
Dose 4 — Pfizer-BioNTech
-
2022-09-16
Health check-in — days 1–6 daily, dose 4Feeling: Fair · Site: Pain, Itching · Fever · Chills, Headache, Muscle or body aches, Fatigue or tirednessAdult check-in
-
2022-09-17
Health check-in — days 1–6 daily, dose 4Feeling: Good · Site: Pain · Headache, Muscle or body aches, Fatigue or tirednessAdult check-in
- 2022-09-18
- 2022-09-19
- 2022-09-20
- 2022-09-21
- 2022-09-22
- 2022-09-29
- 2022-10-06
- 2022-10-13
- 2022-10-20
- 2022-10-27
- 2022-12-17
- 2023-03-18
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-04-20 | Pfizer-BioNTech | |
| 2 | 2021-05-11 | Pfizer-BioNTech | |
| 3 | 2021-11-10 | Pfizer-BioNTech | No |
| 4 | 2022-09-15 | Pfizer-BioNTech | No |
Call center
1 call center case
1 successful
Free text
Release 11 — 3 months, dose 3
Symptoms: Gestational hypertension and Postpartum preeclampsia
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Gestational hypertension | · | · | ✓ |
| SD | Postpartum state | · | · | ✓ |
| SD | Pre-eclampsia | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release